Robust scoring of selective drug responses for patient-tailored therapy selection

Yingjia Chen, Liye He, Aleksandr Ianevski, Pilar Ayuda-Durán, Swapnil Potdar, Jani Saarela, Juho J. Miettinen, Sari Kytölä, Susanna Miettinen, Mikko Manninen, Caroline A. Heckman, Jorrit M. Enserink, Krister Wennerberg, Tero Aittokallio

Published: 2023-11-23 DOI: 10.1038/s41596-023-00903-x

Selective drug-sensitivity scoring

Personalized therapy

Precision medicine

Drug toxicity

R-codes

AI 解读

Extraction of nuclei from archived postmortem tissues for single-nucleus sequencing applications

High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation

Longitudinal interrogation of sympathetic neural circuits and hemodynamics in preclinical models

Experimental modulation of physiological force application on leg joint neurons in intactDrosophila melanogaster

Combining surface-accessible Ag and Au colloidal nanomaterials with SERS for in situ analysis of molecule–metal interactions in complex solution environments

Generation of mouse–human chimeric embryos

Labeling and tracking of immune cells in ex vivo human skin

Large-scale preparation of fluorescence multiplex host cell reactivation (FM-HCR) reporters

Mutate-and-chemical-shift-fingerprint (MCSF) to characterize excited states in RNA using NMR spectroscopy

Comprehensive multi-attribute method workflow for biotherapeutic characterization and current good manufacturing practices testing

查看全部

Sections

Figures

References

Kornauth, C. et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 12, 372–387 (2022).
Malani, D. et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 12, 388–401 (2022).
Letai, A., Bhola, P. & Welm, A. L. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 40, 26–35 (2022).
Tognon, C. E., Sears, R. C., Mills, G. B., Gray, J. W. & Tyner, J. W. Ex vivo analysis of primary tumor specimens for evaluation of cancer therapeutics. Annu. Rev. Cancer Biol. 5, 39–57 (2021).
Flobak, Å., Skånland, S. S., Hovig, E., Taskén, K. & Russnes, H. G. Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. Trends Pharmacol. Sci. 43, 973–985 (2022).
Pemovska, T. et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 519, 102–105 (2015).
Hatzis, C. et al. Enhancing reproducibility in cancer drug screening: how do we move forward? Cancer Res. 74, 4016–4023 (2014).
Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389–393 (2013).
Yadav, B. et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, 5193 (2014).
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).
Mpindi, J. P. et al. Consistency in drug response profiling. Nature 540, E5–E6 (2016).
Pemovska, T. et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 3, 1416–1429 (2013).
Yin, Y. et al. Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia. Clin. Cancer Res. 28, 4444–4455 (2022).
Andersen, A. N. et al. Clinical forecasting using ex vivo drug sensitivity profiling of acute myeloid leukemia. Preprint at https://www.biorxiv.org/content/10.1101/2022.10.11.509866v2 (2023).
Bottomly, D. et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell 40, 850–864.e9 (2022).
Potdar, S. et al. Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data. Nucleic Acids Res. 51, W57–W61 (2023).
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882–883 (2012).
Yamada, S. et al. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia 15, 1892–1897 (2001).
Volm, M. & Efferth, T. Prediction of cancer drug resistance and implications for personalized medicine. Front. Oncol. 5, 282 (2015).
Gupta, A., Gautam, P., Wennerberg, K. & Aittokallio, T. A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening. Commun. Biol. 3, 42 (2020).
Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521–527 (2016).
Murumagi, A. et al. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. Br. J. Cancer 128, 678–690 (2023).
Heinemann, T. et al. Deep morphology learning enhances ex vivo drug profiling-based precision medicine. Blood Cancer Discov. 3, 502–515 (2022).
Kropivsek, K. et al. Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma. Nat. Cancer 4, 734–753 (2023).
Kuusanmäki, H. et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica 105, 708–720 (2020).
Ianevski, A. et al. Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Sci. Adv. 7, eabe4038 (2021).
Goh, J. et al. An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma. Sci. Transl. Med. 14, eabn7824 (2022).
He, L. et al. Patient-customized drug combination prediction and testing for T-cell prolymphocytic leukemia patients. Cancer Res. 78, 2407–2418 (2018).
He, L. et al. Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer. Brief. Bioinform. 22, bbab272 (2021).
Hanes, R. et al. screenwerk: a modular tool for the design and analysis of drug combination screens. Bioinformatics 39, btac840 (2023).
Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose-response analysis using R. PLoS One 10, e0146021 (2015).
Tipping, M. E. & Bishop, C. M. Probabilistic principal component analysis. J. R. Stat. Soc. Ser. B Stat. Methodol. 61, 611–622 (1999).
Lee, S. H. R. et al. Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response. Nat. Med. 29, 170–179 (2023).
Kuusanmäki, H. et al. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica 108, 1768–1781 (2023).
Majumder, M. M. et al. Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget 8, 56338–56350 (2017).
Pearson, K. LIII. On lines and planes of closest fit to systems of points in space. The Lond., Edinb. Dublin Philos. Mag. J. Sci. 2, 559–572 (1901).

Robust scoring of selective drug responses for patient-tailored therapy selection

Supplementary information

推荐阅读